Vectus gets a clearer FDA path for VB0004 lung fibrosis trial
Vectus Biosystems has received supportive written FDA feedback on VB0004, reducing uncertainty around the drug candidate’s manufacturing, nonclinical and planned clinical development package. The company will now incorporate the guidance into an IND application for a Phase Ib/IIa study in IPF patients in Australia.
- Supportive FDA responses on VB0004’s CMC, nonclinical and clinical packages
- Guidance covers the planned Phase Ib/IIa IPF study
- IND package being finalised with Cardinal Health Regulatory Sciences
- Study is planned to commence in Australia
- FDA feedback does not itself authorise the clinical trial
Add us as a preferred source on Google
FDA feedback clears a regulatory hurdle for VB0004
Vectus Biosystems Limited (ASX:VBS) has received supportive written feedback from the US Food and Drug Administration on VB0004, its oral therapy candidate for idiopathic pulmonary fibrosis. The responses address the chemistry, manufacturing and controls package, nonclinical evidence, proposed dose range and design of the planned Phase Ib/IIa study.
The update advances the same regulatory thread as the FDA Type B meeting acceptance reported last month. Vectus had submitted its Pre-IND briefing package in October, seeking the FDA’s views on the drug substance and product manufacturing packages, the supporting toxicology and the proposed pathway for VB0004 in IPF.
IND preparation moves to the next stage
Vectus said it will incorporate the agency’s responses into the Investigational New Drug application now being prepared with Cardinal Health Regulatory Sciences. The company’s stated objective is to complete the package and move VB0004 into its first study in patients with IPF.
Chief Executive Officer and Chief Technology Officer Dr Tara Speranza described the guidance as giving the company “a clear path for the IND”, while stressing that the FDA’s answers will shape the package submitted. VB0004 has already completed Phase Ia clinical studies, which the company says established a favourable safety and pharmacokinetic profile, but the next study will be the first in patients with IPF.
Australian Phase Ib/IIa study remains the key catalyst
The planned Phase Ib/IIa trial is set to commence in Australia. The announcement does not provide an IND submission date, an effective date for the application, a trial start timetable, patient numbers or any efficacy data. Nor does supportive Pre-IND feedback amount to clinical-trial authorisation.
That leaves execution, funding and the eventual clinical readout as the more consequential tests ahead. The company has received useful regulatory direction, but the filing stops short of saying when patients will be dosed or how the study will be financed. For Vectus, the next meaningful evidence of momentum should come from completion and submission of the IND, followed by a confirmed trial start.
Bottom Line?
The FDA has helped narrow the regulatory questions around VB0004, but the investment story now turns on IND submission, funding and the timing of first patient dosing.
Questions in the middle?
- When will Vectus submit the VB0004 IND and provide a target date for trial commencement?
- What funding will be required to complete the IND process and run the Australian Phase Ib/IIa study?
- Will the planned patient study reproduce VB0004’s favourable Phase Ia safety and pharmacokinetic profile in people with IPF?
Sources
1-
FDA Pre-IND feedback for VB0004 (opens in a new tab)Official market announcement. Vectus Biosystems Limited · 16 Nov 2026 · vectusbiosystems.com.au